Trial Profile
Prospective study for clarification of mechanisms of acquired resistance for afatinib using plasma samples
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 Aug 2019
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Feb 2017 New trial record